

## Special Issue

# Advancements in the Epidemiology, Diagnosis and Treatment of Hypertrophic Cardiomyopathy

### Message from the Guest Editor

Hypertrophic cardiomyopathy is a heterogeneous clinical disorder with a variable morphologic expression and an increasingly recognized prevalence in the cardiovascular patient community. In the past decade, we have seen exponential growth in the available modalities for patient diagnosis and risk stratification, as well as in treatment options ranging from medical therapy to percutaneous and surgical interventions. The aim of this Special Issue is to highlight this progress from the perspective of international experts across multi-disciplinary modalities via review articles, brief editorials, case reports, or original research. We encourage all interested authors to submit their work and share their experiences of this growing and complex patient population.

### Guest Editor

Dr. Christos G. Mihos

Division of Cardiology, Mount Sinai Heart Institute, Columbia University  
Irving Medical Center, Miami Beach, FL 33140, USA

### Deadline for manuscript submissions

30 September 2025



**Journal of  
Cardiovascular  
Development and  
Disease**

---

an Open Access Journal  
by MDPI

---

**Impact Factor 2.3  
CiteScore 3.7  
Indexed in PubMed**



[mdpi.com/si/194351](https://mdpi.com/si/194351)

*Journal of Cardiovascular  
Development and Disease*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcdd@mdpi.com](mailto:jcdd@mdpi.com)

[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)





# Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.3  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)



## About the Journal

### Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

---

### Editor-in-Chief

Prof. Dr. Thomas Brand  
National Heart & Lung Institute, Imperial College London, South  
Kensington Campus, London SW7 2AZ, UK

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /  
CiteScore - Q2 (General Pharmacology, Toxicology and  
Pharmaceutics)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).